Generic Dacomitinib for Lung Cancer Mutations

This medication, Dacomitinib, is an EGFR inhibitor It’s used for treating NSCLC, the kind of lung cancer that’s not small cell It works specifically on those NSCLC cases with mutations in the EGFR gene, Including ones with EGFR 19 deletion mutations or 21 L858R changes. There are three dosing options: You can get it in doses of 15 mg, 30 mg, or 45 mg, And each of those doses is a film-coated pill.

The usual is 45 mg, taken every day. They come in bottles with 30 tablets each.